The amino acid and sugar composition of mucins from various organs is similar but not identical. This could arise by one or more of the following: organ-specific processing of a single core protein, organ-specific splicing of a single mucin mRNA, or organ-specific expression of various mucin genes. To begin to investigate the source ofthis variability, we examined (a) immunological cross-reactivity and (b) cDNA cross-hybridization, among several mucin-secreting organs of the human body. Peptide-directed antibodies raised against both nondeglycosylated (LS) and deglycosylated (HFB) intestinal mucin strongly stained mucous cells in the bronchial epithelium and submucosal glands, indicating homology between mucins of the bronchus and intestine at the peptide level. By screening a bronchus cDNA library with an intestinal mucin cDNA, SMUC-41, we isolated a bronchus mucin cDNA, HAM-1. This cDNA is 96% homologous to the first repeat of SMUC-41. HAM-I hybridized to restriction fragments of human genomic DNA identical to those hybridizing to SMUC-41 on Southern blots. SMUC-41 also hybridized to polydisperse transcripts in the bronchus, cervix, gall bladder, and mammary gland, indicating mucin homology among all these organs at the RNA level. We conclude that the bronchus and intestine express a common mucin gene, which is likely co-expressed by at least several other mucin-secreting organs. (J. Clin. Invest. 1991. 87:7742.)
Introduction
Mucin is a high-molecular weight glycoprotein that plays important roles at several mucosal surfaces of the body including respiratory (1), gastrointestinal (2) , and urogenital (3) tracts. Biochemical analysis of purified mucins from various human tissues shows that they share several general properties: high molecular weight (> 106 D), high carbohydrate content (70-80%), and oligosaccharides consisting of N-acetyl galactosamine, galactose, fucose, sialic acid, and N-acetyl glucosamine (4) . The latter are joined by O-glycosidic linkages to the core protein or apomucin, which is typically rich in hydroxyamino acids (2, (5) (6) (7) . However, despite these similarities, extensive microheterogeneity exists, with mucins from various sources showing different stoichiometry of amino acids and sugars (compare 5, 7-9) .
The significance of the biochemical differences between mucins has remained obscure. One possibility is that different mucin genes are expressed in different organs to serve organspecific functions. Thus, mucin of the respiratory tract, whose principal role is in mucociliary clearance (1), differs chemically from mucin in the cervix, whose principal role is in fertilization (10) . It has been disputed as to whether these diverse functions could be served by a single mucin gene. Recently, apomucin cDNAs have been cloned from human mammary tumor ( 11) and intestine (12) . Although full-length cDNAs have not yet been reported, nucleotide and amino acid comparison indicates no similarities, except for the presence of tandem repeats of different lengths. Chromosome mapping shows the two genes are located on different chromosomes, supporting a one-organ-one-gene hypothesis. On the other hand, a comparison of amino acid composition between airway and intestinal mucins (2, 7, 8) revealed a high degree of similarity. Furthermore, recent data showed that antibodies raised against the core protein ofbronchial mucin cross-reacted with mucin in intestinal goblet cells, strengthening the possibility of close structural homology between mucins from the two organs (13) . On this basis, it seemed possible that the airways and the intestinal tract might express a single, or two closely related, mucin genes.
Using an intestinal mucin cDNA, SMUC 41 (12), we have shown that the same mucin gene is not only expressed in the airways and intestine, but is homologous to a gene or genes expressed in the gallbladder, cervix, and mammary gland. Using this cDNA, we have isolated a mucin cDNA from human bronchus whose properties confirm its relationship to the SMUC-41 gene. This cDNA should prove useful in studies of the regulation of mucin gene expression in disorders such as cystic fibrosis (14) , chronic bronchitis (15) (16) (17) , and bronchial carcinoma (17-21).
Methods
Histology and immunocytochemistry. Antibodies used in this study were described previously (12, 22) . Briefly, mucin was purified from nude mouse xenografts of LS1 74T human colon carcinoma cells and deglycosylated using anhydrous hydrogen fluoride. Rabbit polyclonal antibodies were raised by using untreated mucin (LS), partially deglycosylated product predominantly consisting of GalNac-apomucin (HFA), and totally deglycosylated mucin (HFB) as immunogens.
Paraffin sections (5 Mm) of surgical specimens of human bronchial tissue were deparaffinized before routine staining with hematoxylin and eosin or prepared for immunocytochemistry. For immunocytochemistry, sections were rinsed in PBS and then blocked in 5% normal rabbit serum in PBS. All reactions were carried out at room temperature. Antibodies were diluted in PBS. Antibody was applied to sections for 2 h. After rinsing, sections were incubated with second antibody consisting of goat anti-rabbit IgG-biotin. After rinsing, sections were incubated with streptavidin-peroxidase conjugate, and rinsed again before development of the reaction with diaminobenzidine. Sections were counterstained with methyl green, covered with Permount, and photographed using a Zeiss photomicroscope.
RNA blots. Total RNA was extracted from human airways and other human tissues as described (23 Construction and screening ofa bronchus cDNA library. RNA was extracted as described above from a surgical specimen from a patient with chronic bronchitis. Polyadenylated RNA was enriched by oligodTcolumn chromatography (Pharmacia Fine Chemicals, Inc., Piscataway, NJ). mRNA was tested by in vitro translation (rabbit reticulocyte lysate, Amersham Corp.). 5 ,g ofpoly-A' RNA were used for synthesis ofoligo-dT-primed cDNA, using Amersham's cDNA Synthesis System Plus. Double-stranded cDNA was cloned into the EcoRI site oflambda ZAP II (Stratagene, La Jolla, CA) using Gigapack Gold as a packaging kit (Stratagene). Screening of the library was performed at 3,000 pfu/ 150-mm plate. Plaque lifting to duplicate nitrocellulose filters (Schleicher & Schuell, Keene, NH) was carried out as described (25) . Hybridization, washing, and autoradiography were performed essentially as described above, except that 5X SSC was used in the hybridization solution.
Sequencing. Bluescript vector containing the insert of interest was prepared by in vivo excision (26) . Nucleotide sequence ofboth strands was determined by the dideoxy chain termination method (27) using [35S]dATP (Amersham Corp.) and modified T7 DNA polymerase (United States Biochemical Corp., Cleveland, OH).
Results
The LS antibody raised against nondeglycosylated intestinal adenocarcinoma mucin stained mature secretory granules in goblet cells of the bronchial epithelium (data not shown) in a similar fashion to that reported for intestinal goblet cells (21) . LS antibody also recognized secretory granules in cells of the submucosal glands. Some gland tubules were negative, presumably representing serous gland cells, and possibly including some mucous cells. The HFA antibody, raised against partially deglycosylated mucin, stained mucous gland, and goblet cells below and around the mucous granules ( Fig. 1 D) , probably targeting the Golgi apparatus. Using the HFB antibody, raised against totally deglycosylated mucin core protein, reactive areas were below and around the mucous granules, probably targeting both the rough endoplasmic reticulum and Golgi apparatus (Fig. 1 B) . These data provide evidence that mucin core proteins structurally related to those in the intestine are expressed in the bronchus. Although goblet cells and mucous gland cells reacted with the three antibodies, a subpopulation was unreactive, suggesting the existence ofother types ofmucin molecules.
To evaluate the similarity between airway and intestinal mucin at the mRNA level, we performed Northern blots and compared SMUC 41 hybridization signals in RNA from airways and intestine. RNA was extracted from tumor-free colon and bronchus specimens removed during tumor surgery from two individuals. The bronchus tissue was from a smoker with chronic bronchitis. Hybridization of bronchus poly (A)' RNA with the human small intestinal mucin cDNA SMUC 41 was first performed under low-stringency washing conditions (2x SSC, 50'C). The signal persisted, however, under high-stringency washing conditions (0.2x SSC, 630C), indicating a high degree of homology between human intestinal and airway mucin mRNAs. The airway mucin mRNA showed a polydisperse hybridization signal similar to that in the intestine (Fig. 2 , also see reference 12). That RNA degradation did not account for the observed polydispersity was indicated by the fact that the RNA showed sharp ribosomal bands on ethidium bromide stained agarose gels. This was supported by reprobing the same blots with a beta-actin probe, which revealed sharp bands ofthe expected size (Fig. 2) . Based on accumulating data from several laboratories (12, 30) , polydispersity is considered an inherent property of mucin mRNA.
To further investigate the degree of homology between intestinal and airway mucin, we used the intestinal mucin probe SMUC 41 to isolate a cDNA encoding airway mucin. We constructed an airway library consisting of 350,000 independent recombinants before amplification. Screening of 30,000 plaque-forming units (pfu) of the unamplified library under highly stringent conditions with SMUC 41 yielded one strongly positive signal. After rescreening to clonality and in vivo excision of pBluescript vector, sequencing was performed on both strands. The sequence ofthe bronchus cDNA fragment HAM-1 is highly homologous to the first repeat of the intestinal mucin cDNA SMUC 41 (Fig. 3 A) . The deduced amino acid sequence differs in four amino acids, but contains a copy of the highly conserved sequence TTTTVTPTPTPT characteristic of the three intestinal mucin cDNAs previously described (12) (Fig. 3 B) . The four amino acid substitutions were confirmed by bidirectional sequencing of an identical insert in a different clone. We interpret this substituted sequence to represent a repeat not contained in SMUC 40-41, but present on the same transcript.
As expected, hybridization of the intestinal mucin cDNA SMUC 41 and the bronchus cDNA HAM-1 to restriction fragments (Apa I and Hind III) of human genomic DNA yielded identical bands at 13.0 (Apa I) and 9.0 kb (Hind III) (Fig. 4) tween intestinal and bronchial mucins, we analyzed them at the level of RNA, using an intestinal mucin-specific cDNA, SMUC 41 (12) . Hybridization ofbronchial RNA to SMUC-41 survived high-stringency washing conditions (Fig. 2) , supporting the possibility that the bronchus shared with the intestine expression of the SMUC mucin gene. This led us to screen a human bronchial cDNA library with SMUC-41, permitting the isolation ofa bronchial mucin cDNA, HAM-1. This cDNA shows 96% homology to the first repeat of SMUC 41 as well as conservation of the highly conserved sequence TTTTVTPTPTPT common to the three intestinal mucin cDNAs previously described ( 12) . Together with the data from genomic Southern blots (Fig. 4) , showing that the intestinal and bronchial mucin cDNAs hybridize to the same restriction fragments, these data indicate that the bronchus expresses a mucin gene also expressed by the intestine. All ofthe bronchus RNA used in this study was taken from individuals with chronic bronchitis. In view of the abnormally high mucus production seen in this disease, it is possible that mucin gene expression is itselfabnormal. Ifso, the SMUC-like transcripts we observed by both Northern blot and library screening may be peculiar to diseased airways. Because it is difficult to obtain RNA from healthy human airways, the question of whether SMUC or other mucin genes are expressed in the absence of disease must remain open at this time. Recent evidence (29) has shown that antibodies directed against intestinal mucin (LS, HFA, HFB) cross-react with mucin-producing organs deriving embryologically from endoderm (bronchus and intestine), but not ectoderm (urogenital tract) or mesoderm (mammary gland). Extending the analysis to the RNA level in the present study, we obtained SMUC 41 hybridization signals, under high stringency washing conditions, from gall bladder (endodermal), cervix (ectodermal), and mammary gland (mesodermal). This indicates that expression of the SMUC-41 cognate gene is widespread throughout the mucin-producing organs of the human body. RNA processing or posttranscriptional modifications of the core protein may account for the differences observed between our hybridization data and the immunocytochemical data reported by Yan et al. (29) .
The total number ofhuman mucin genes and their possible coexpression by various organs is currently unknown. The present study provides the first evidence for coexpression ofa single mucin gene in at least two separate organs (intestine and bronchus). It is likely from immunocytochemical studies that the PUM mucin gene is also expressed in two different organs (mammary gland and lung 30, 31) . Much remains to be learned about the nature of organ-specific processing of these co-expressed genes, at the level of both RNA and peptide. The present data on the expression ofthe SMUC gene in the human bronchus is the fourth example of a mucin-secreting organ producing mucin with the property of tandem repeats. Other examples are the mammary gland tumor mucin (I 1), the human SMUC intestinal mucin (12) , and the porcine submandibular gland mucin (32) . The repeat structure apparently represents a modular glycosylation unit. Each threonine-rich peptide repeat should present similar or identical glycosylation sites for cellular glycosyltransferases. The presence of tandem repeats means that despite considerable heterogeneity, there may exist ordered domains of specific oligosaccharide chains repeating n times. The modular nature ofthe mucin monomer should lend itselfto length modification by alternative splicing, a phenomenon which could account for the remarkable polydispersity of mucin message length (this paper, 12, 30) .
Alternative splicing could be achieved by retained introns, the presence of alternate 5' donor and 3' acceptor sites, the use of alternative promotors and polyadenylation sites, internal mutually exclusive exons or cassette exons (for review 33). Consistent with this possibility is the observed polydispersity in (a) the length of bronchial glycoproteins (8) , (b) the molecular weight of mucin precursors (34) , and (c) the molecular weight of deglycosylated mucin peptides (13) .
Heterogeneous subpopulations of epithelial goblet or mucous gland cells may contribute to the observed polydispersity, since biochemically distinct subpopulations of mucous cells have been identified in both the intestine (35) and airways (36) . Whatever the mechanism, the ability of a cell to modulate the length of the mucin monomer should enable it to influence mucus gel stability (resistance to dispersion) because the latter parameter is proportional to the square of the average monomer length (37).
Mucus hypersecretion is a key symptom of chronic bronchitis (15) and is correlated with the subsequent development oflung cancer (17, 21). The pathogenesis ofhypersecretion has been difficult to understand due to the lack of biochemical markers. The availability of mucin cDNAs will facilitate studies of hypersecretion by providing tools with which to monitor steady-state levels of mucin mRNA in various pathological samples. Ultimately, analysis of the regulatory regions of mucin genes should reveal how mucin production is controlled at the first biosynthetic control point, that of mRNA transcription.
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